Medical Condition News

RSS

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

Home visits to educate children with asthma can lead to fewer flare-ups and less frequent trips to ER

A few home visits by a health care specialist to educate children with asthma about basic strategies for earlier symptom recognition and improving medication use can lead to fewer flare-ups and less frequent trips to the ER, according to research from Johns Hopkins Children's Center published in the December issue of Pediatrics.

1 Dec 2009

New research suggests people cannot survive cardiac arrest without oxygen during CPR

People can survive cardiac arrest if they receive only chest compressions during attempts to revive them - as advised by the current American Heart Association guidelines. But they cannot survive without access to oxygen sometime during the resuscitation effort, research suggests.

1 Dec 2009

Americans living in the Southern region may have elevated risk of dying from stroke

The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.

1 Dec 2009

CPR/AED education program for teens

Be the Beat, the American Heart Association's new online cardiac arrest awareness campaign, teaches 12- to 15-year-olds fun ways to learn the basics of cardiopulmonary resuscitation (CPR) and how to use an automated external defibrillator (AED).

30 Nov 2009

Alzheimer's Association offers tips and round the clock assistance for caregivers during holiday season

In Massachusetts, approximately 70% of those with Alzheimer's disease are cared for at home, so the Alzheimer's Association is preparing for a surge in calls to its 24/7 Helpline during the holiday season. For most families, holidays are filled with opportunities for togetherness and sharing, but for a family dealing with Alzheimer's, holidays can also be stressful and filled with special challenges, according to the experts at the Alzheimer's Association.

30 Nov 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

QRxPharma commences Phase 3 pivotal trial of MoxDuo IR

QRxPharma Limited announced today, as part of its Phase 3 program, the initiation of a registration (also called pivotal) trial (Study 008) comparing efficacy and safety profiles of MoxDuo(TM)IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery. The Company expects to complete dosing by close of Q2 2010.

30 Nov 2009

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U.

30 Nov 2009

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

30 Nov 2009

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).

30 Nov 2009

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products. With this step, MagForce has now commenced the conformity assessment procedure for its Nano-Cancer ® therapy.

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

A multidisciplinary team from the Montreal Heart Institute (MHI) performed its first catheter implantation of a new prosthesis (Amptlazer(R) Cardiac Plug) closing the appendage of the left atrium of the heart, which will have the effect of preventing the formation of blood clots and avoiding open-heart surgery. This is excellent news for patients suffering from atrial fibrillation, the most common form of cardiac arrhythmia, affecting at least 5% of Canadians over the age of 70.

30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Presentations at Tuesday's RSNA conference

A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.

30 Nov 2009

Medical Condition News

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

Home visits to educate children with asthma can lead to fewer flare-ups and less frequent trips to ER

New research suggests people cannot survive cardiac arrest without oxygen during CPR

Americans living in the Southern region may have elevated risk of dying from stroke

CPR/AED education program for teens

Alzheimer's Association offers tips and round the clock assistance for caregivers during holiday season

Clinical trials of personalised vaccines to fight glioblastomas

QRxPharma commences Phase 3 pivotal trial of MoxDuo IR

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

Kiadis Pharma commences enrollment in multinational ATIR study

Allos Therapeutics granted U.S. patent for FOLOTYN

Eli Lilly's Cymbalta receives FDA approval

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

Micromet to present new results from its blinatumomab study at the ASH meeting

ALS research collaboration receives philanthropic funding

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Presentations at Tuesday's RSNA conference

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News